Global Terbinafine Tablet Market
Global Terbinafine Tablet Market

Terbinafine Tablet Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Oral Medication, External Medicine), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Patient (Adult Dose, Paediatric Dose) Players and Region - Global Market Outlook to 2026

Terbinafine Tablet Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 250 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Terbinafine TabletMarket?
Terbinafine is used to treat certain types of fungal infections (for example, of the fingernail or toenail). It works by stopping the growth of fungus. This medication belongs to a class of drugs known as antifungals. The use of these drugs is as an antifungal medication that fights infections caused by fungus. Terbinafine tablets are used to treat infections caused by a fungus that affect the fingernails or toenails. Terbinafine oral granules are used to treat a fungal infection of scalp hair follicles in children who are at least 4 years old.

Market Trend
Growing in the number of online pharmacies

Market Drivers
Increasing sports and event worldwide and The rise in the prevalence of skin infection such as ringworm

Opportunities
The increasing number of cases of dermatological related diseases drives the tinea corporis drugs to demand in the market

The Players Covered in the Study are:
Novartis (Switzerland), GSK (United Kingdom), TEVA (Israel), Dr. Reddy's Laboratories(India), CIPLA LTD (India), Quimica Sintetica S.A. (Spain), Dipharma (United States), InvaGen Pharmaceuticals (United States), Breckenridge Pharmaceutical(United States) and Harris Pharmaceutical(United States)

Available Customization:
List of players that can be included in the study on immediate basis are Glenmark (India), Orchid Healthcare (India), APOTEX (Canada) and Jilin Wantong Group (China).

Report Objectives / Segmentation Covered
By Application
  • Athlete's Foot
  • Jock Itch
  • Ringworm
  • Others
By Route of Administration
  • Oral Medication
  • External Medicine

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Patient
  • Adult Dose
  • Paediatric Dose

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing sports and event worldwide
      • 3.2.2. The rise in the prevalence of skin infection such as ringworm
    • 3.3. Market Challenges
      • 3.3.1. Use of homemade therapy as a substitute
    • 3.4. Market Trends
      • 3.4.1. Growing in the number of online pharmacies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Terbinafine Tablet, by Application, Route of Administration, Distribution Channel, Patient and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Terbinafine Tablet (Value)
      • 5.2.1. Global Terbinafine Tablet by: Application (Value)
        • 5.2.1.1. Athlete's Foot
        • 5.2.1.2. Jock Itch
        • 5.2.1.3. Ringworm
        • 5.2.1.4. Others
      • 5.2.2. Global Terbinafine Tablet by: Route of Administration (Value)
        • 5.2.2.1. Oral Medication
        • 5.2.2.2. External Medicine
      • 5.2.3. Global Terbinafine Tablet by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
      • 5.2.4. Global Terbinafine Tablet by: Patient (Value)
        • 5.2.4.1. Adult Dose
        • 5.2.4.2. Paediatric Dose
      • 5.2.5. Global Terbinafine Tablet Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Terbinafine Tablet: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GSK (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TEVA (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr. Reddy's Laboratories(India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CIPLA LTD (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Quimica Sintetica S.A. (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dipharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. InvaGen Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Breckenridge Pharmaceutical(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Harris Pharmaceutical(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Terbinafine Tablet Sale, by Application, Route of Administration, Distribution Channel, Patient and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Terbinafine Tablet (Value)
      • 7.2.1. Global Terbinafine Tablet by: Application (Value)
        • 7.2.1.1. Athlete's Foot
        • 7.2.1.2. Jock Itch
        • 7.2.1.3. Ringworm
        • 7.2.1.4. Others
      • 7.2.2. Global Terbinafine Tablet by: Route of Administration (Value)
        • 7.2.2.1. Oral Medication
        • 7.2.2.2. External Medicine
      • 7.2.3. Global Terbinafine Tablet by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
      • 7.2.4. Global Terbinafine Tablet by: Patient (Value)
        • 7.2.4.1. Adult Dose
        • 7.2.4.2. Paediatric Dose
      • 7.2.5. Global Terbinafine Tablet Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Terbinafine Tablet: by Application(USD Million)
  • Figure 4. Global Terbinafine Tablet: by Application USD Million (2015-2020)
  • Table 2. Terbinafine Tablet Athlete's Foot , by Region USD Million (2015-2020)
  • Table 3. Terbinafine Tablet Jock Itch , by Region USD Million (2015-2020)
  • Table 4. Terbinafine Tablet Ringworm , by Region USD Million (2015-2020)
  • Table 5. Terbinafine Tablet Others , by Region USD Million (2015-2020)
  • Table 6. Terbinafine Tablet: by Route of Administration(USD Million)
  • Figure 5. Global Terbinafine Tablet: by Route of Administration USD Million (2015-2020)
  • Table 7. Terbinafine Tablet Oral Medication , by Region USD Million (2015-2020)
  • Table 8. Terbinafine Tablet External Medicine , by Region USD Million (2015-2020)
  • Table 9. Terbinafine Tablet: by Distribution Channel(USD Million)
  • Figure 6. Global Terbinafine Tablet: by Distribution Channel USD Million (2015-2020)
  • Table 10. Terbinafine Tablet Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Terbinafine Tablet Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 12. Terbinafine Tablet Online Pharmacy , by Region USD Million (2015-2020)
  • Table 13. Terbinafine Tablet: by Patient(USD Million)
  • Figure 7. Global Terbinafine Tablet: by Patient USD Million (2015-2020)
  • Table 14. Terbinafine Tablet Adult Dose , by Region USD Million (2015-2020)
  • Table 15. Terbinafine Tablet Paediatric Dose , by Region USD Million (2015-2020)
  • Table 16. South America Terbinafine Tablet, by Country USD Million (2015-2020)
  • Figure 8. South America Terbinafine Tablet Share (%), by Country
  • Table 17. South America Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 18. South America Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 19. South America Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 20. South America Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 21. Brazil Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 22. Brazil Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 23. Brazil Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 24. Brazil Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 25. Argentina Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 26. Argentina Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 27. Argentina Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 28. Argentina Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 29. Rest of South America Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 31. Rest of South America Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 32. Rest of South America Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 33. Asia Pacific Terbinafine Tablet, by Country USD Million (2015-2020)
  • Figure 9. Asia Pacific Terbinafine Tablet Share (%), by Country
  • Table 34. Asia Pacific Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 36. Asia Pacific Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 37. Asia Pacific Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 38. China Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 39. China Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 40. China Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 41. China Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 42. Japan Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 43. Japan Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 44. Japan Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 45. Japan Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 46. India Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 47. India Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 48. India Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 49. India Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 50. South Korea Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 51. South Korea Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 52. South Korea Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 53. South Korea Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 54. Taiwan Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 55. Taiwan Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 56. Taiwan Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 57. Taiwan Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 58. Australia Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 59. Australia Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 60. Australia Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 61. Australia Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 66. Europe Terbinafine Tablet, by Country USD Million (2015-2020)
  • Figure 10. Europe Terbinafine Tablet Share (%), by Country
  • Table 67. Europe Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 68. Europe Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 69. Europe Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 70. Europe Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 71. Germany Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 72. Germany Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 73. Germany Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 74. Germany Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 75. France Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 76. France Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 77. France Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 78. France Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 79. Italy Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 80. Italy Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 81. Italy Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 82. Italy Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 83. United Kingdom Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 85. United Kingdom Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 86. United Kingdom Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 87. Netherlands Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 88. Netherlands Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 89. Netherlands Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 90. Netherlands Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 91. Rest of Europe Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 93. Rest of Europe Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 94. Rest of Europe Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 95. MEA Terbinafine Tablet, by Country USD Million (2015-2020)
  • Figure 11. MEA Terbinafine Tablet Share (%), by Country
  • Table 96. MEA Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 97. MEA Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 98. MEA Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 99. MEA Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 100. Middle East Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 101. Middle East Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 102. Middle East Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 103. Middle East Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 104. Africa Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 105. Africa Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 106. Africa Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 107. Africa Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 108. North America Terbinafine Tablet, by Country USD Million (2015-2020)
  • Figure 12. North America Terbinafine Tablet Share (%), by Country
  • Table 109. North America Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 110. North America Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 111. North America Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 112. North America Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 113. United States Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 114. United States Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 115. United States Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 116. United States Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 117. Canada Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 118. Canada Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 119. Canada Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 120. Canada Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Table 121. Mexico Terbinafine Tablet, by Application USD Million (2015-2020)
  • Table 122. Mexico Terbinafine Tablet, by Route of Administration USD Million (2015-2020)
  • Table 123. Mexico Terbinafine Tablet, by Distribution Channel USD Million (2015-2020)
  • Table 124. Mexico Terbinafine Tablet, by Patient USD Million (2015-2020)
  • Figure 13. Global Terbinafine Tablet share by Players 2020 (%)
  • Figure 14. Global Terbinafine Tablet share by Players (Top 3) 2020(%)
  • Figure 15. Global Terbinafine Tablet share by Players (Top 5) 2020(%)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Terbinafine Tablet: by Application(USD Million)
  • Figure 37. Global Terbinafine Tablet: by Application USD Million (2021-2026)
  • Table 136. Terbinafine Tablet Athlete's Foot , by Region USD Million (2021-2026)
  • Table 137. Terbinafine Tablet Jock Itch , by Region USD Million (2021-2026)
  • Table 138. Terbinafine Tablet Ringworm , by Region USD Million (2021-2026)
  • Table 139. Terbinafine Tablet Others , by Region USD Million (2021-2026)
  • Table 140. Terbinafine Tablet: by Route of Administration(USD Million)
  • Figure 38. Global Terbinafine Tablet: by Route of Administration USD Million (2021-2026)
  • Table 141. Terbinafine Tablet Oral Medication , by Region USD Million (2021-2026)
  • Table 142. Terbinafine Tablet External Medicine , by Region USD Million (2021-2026)
  • Table 143. Terbinafine Tablet: by Distribution Channel(USD Million)
  • Figure 39. Global Terbinafine Tablet: by Distribution Channel USD Million (2021-2026)
  • Table 144. Terbinafine Tablet Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 145. Terbinafine Tablet Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 146. Terbinafine Tablet Online Pharmacy , by Region USD Million (2021-2026)
  • Table 147. Terbinafine Tablet: by Patient(USD Million)
  • Figure 40. Global Terbinafine Tablet: by Patient USD Million (2021-2026)
  • Table 148. Terbinafine Tablet Adult Dose , by Region USD Million (2021-2026)
  • Table 149. Terbinafine Tablet Paediatric Dose , by Region USD Million (2021-2026)
  • Table 150. South America Terbinafine Tablet, by Country USD Million (2021-2026)
  • Figure 41. South America Terbinafine Tablet Share (%), by Country
  • Table 151. South America Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 152. South America Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 153. South America Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 154. South America Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 155. Brazil Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 156. Brazil Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 157. Brazil Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 158. Brazil Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 159. Argentina Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 160. Argentina Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 161. Argentina Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 162. Argentina Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 163. Rest of South America Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 164. Rest of South America Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 165. Rest of South America Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 166. Rest of South America Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 167. Asia Pacific Terbinafine Tablet, by Country USD Million (2021-2026)
  • Figure 42. Asia Pacific Terbinafine Tablet Share (%), by Country
  • Table 168. Asia Pacific Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 169. Asia Pacific Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 170. Asia Pacific Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 171. Asia Pacific Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 172. China Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 173. China Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 174. China Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 175. China Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 176. Japan Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 177. Japan Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 178. Japan Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 179. Japan Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 180. India Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 181. India Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 182. India Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 183. India Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 184. South Korea Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 185. South Korea Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 186. South Korea Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 187. South Korea Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 188. Taiwan Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 189. Taiwan Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 190. Taiwan Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 191. Taiwan Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 192. Australia Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 193. Australia Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 194. Australia Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 195. Australia Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 200. Europe Terbinafine Tablet, by Country USD Million (2021-2026)
  • Figure 43. Europe Terbinafine Tablet Share (%), by Country
  • Table 201. Europe Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 202. Europe Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 203. Europe Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 204. Europe Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 205. Germany Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 206. Germany Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 207. Germany Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 208. Germany Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 209. France Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 210. France Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 211. France Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 212. France Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 213. Italy Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 214. Italy Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 215. Italy Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 216. Italy Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 217. United Kingdom Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 218. United Kingdom Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 219. United Kingdom Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 220. United Kingdom Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 221. Netherlands Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 222. Netherlands Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 223. Netherlands Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 224. Netherlands Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 225. Rest of Europe Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 226. Rest of Europe Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 227. Rest of Europe Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 228. Rest of Europe Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 229. MEA Terbinafine Tablet, by Country USD Million (2021-2026)
  • Figure 44. MEA Terbinafine Tablet Share (%), by Country
  • Table 230. MEA Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 231. MEA Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 232. MEA Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 233. MEA Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 234. Middle East Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 235. Middle East Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 236. Middle East Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 237. Middle East Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 238. Africa Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 239. Africa Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 240. Africa Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 241. Africa Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 242. North America Terbinafine Tablet, by Country USD Million (2021-2026)
  • Figure 45. North America Terbinafine Tablet Share (%), by Country
  • Table 243. North America Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 244. North America Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 245. North America Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 246. North America Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 247. United States Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 248. United States Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 249. United States Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 250. United States Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 251. Canada Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 252. Canada Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 253. Canada Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 254. Canada Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 255. Mexico Terbinafine Tablet, by Application USD Million (2021-2026)
  • Table 256. Mexico Terbinafine Tablet, by Route of Administration USD Million (2021-2026)
  • Table 257. Mexico Terbinafine Tablet, by Distribution Channel USD Million (2021-2026)
  • Table 258. Mexico Terbinafine Tablet, by Patient USD Million (2021-2026)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 19. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GSK (United Kingdom) Revenue: by Geography 2020
  • Figure 21. TEVA (Israel) Revenue, Net Income and Gross profit
  • Figure 22. TEVA (Israel) Revenue: by Geography 2020
  • Figure 23. Dr. Reddy's Laboratories(India) Revenue, Net Income and Gross profit
  • Figure 24. Dr. Reddy's Laboratories(India) Revenue: by Geography 2020
  • Figure 25. CIPLA LTD (India) Revenue, Net Income and Gross profit
  • Figure 26. CIPLA LTD (India) Revenue: by Geography 2020
  • Figure 27. Quimica Sintetica S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 28. Quimica Sintetica S.A. (Spain) Revenue: by Geography 2020
  • Figure 29. Dipharma (United States) Revenue, Net Income and Gross profit
  • Figure 30. Dipharma (United States) Revenue: by Geography 2020
  • Figure 31. InvaGen Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. InvaGen Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 33. Breckenridge Pharmaceutical(United States) Revenue, Net Income and Gross profit
  • Figure 34. Breckenridge Pharmaceutical(United States) Revenue: by Geography 2020
  • Figure 35. Harris Pharmaceutical(United States) Revenue, Net Income and Gross profit
  • Figure 36. Harris Pharmaceutical(United States) Revenue: by Geography 2020
Some of the key companies/manufacturers profiled in the report
  • Novartis (Switzerland)
  • GSK (United Kingdom)
  • TEVA (Israel)
  • Dr. Reddy's Laboratories(India)
  • CIPLA LTD (India)
  • Quimica Sintetica S.A. (Spain)
  • Dipharma (United States)
  • InvaGen Pharmaceuticals (United States)
  • Breckenridge Pharmaceutical(United States)
  • Harris Pharmaceutical(United States)
Additional players considered in the study are as follows:
Glenmark (India) , Orchid Healthcare (India) , APOTEX (Canada) , Jilin Wantong Group (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation